Rewind Therapeutics secures additional financing to advance its oral GPR17 remyelination program. This funding will help complete key IND-enabling studies and support the clinical development of the therapy.
PRIVATEOct 06, 2026
Round Type
Venture
Leuven
Description
Rewind Therapeutics, a biotechnology company developing therapies for demyelinating diseases, has secured additional financing for its GPR17 antagonist program. This program aims to promote remyelination in multiple sclerosis. The funding allows Rewind to complete critical IND-enabling studies while advancing their research. The company is optimistic about the prospects of its GPR17 program based on recent supportive data.
Company Information
Company
Rewind Therapeutics
Location
Leuven, Flemish Brabant, Belgium
About
Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis or nerve injuries. A common feature of these illnesses is the loss of the myelin sheath, a protective cover wrapped around the nerves. Repairing or re-installing this sheath (i.e., remyelination) is a crucial factor for halting or reversing disease progression or even curing these diseases. Rewind´s team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. Based in Leuven, Belgium, Rewind is backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Sunstone Life Science Ventures, Gemma Frisius Fonds, and CD3/ KU Leuven.
https://rwdtx.com/
Fundz sees it the moment Rewind Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Leuven